Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury

David N. Reynolds, Scott A. Smith, Yi P. Zhang, Qiu Mengsheng, Debomoy Lahiri, Dante J. Morassutti, Christopher B. Shields, Girish J. Kotwal

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Traumatic spinal cord injury (SCI) claims approximately 10,000 new victims each year in the United States alone. The injury usually strikes those under the age of 30 years, often leading to a lifetime of pain, suffering, and disability. Therapeutic agents targeting spinal cord injury are sorely lacking, and therefore our laboratory endeavored to evaluate the potential therapeutic benefits of immediate post-injury administration of the vaccinia virus complement control protein (VCP). VCP is a multifunctional anti-inflammatory protein that can inhibit both pathways of complement activation and bind heparin. Utilizing a common animal model of contusion SCI, motor function recovery tests, and immunochemical stains, we evaluated the effects of VCP injected into spinal cord tissue following injury. Results demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves hind-limb function, establishing VCP as a strong candidate for further investigation in the treatment of SCI.

Original languageEnglish
Pages (from-to)165-178
Number of pages14
JournalAnnals of the New York Academy of Sciences
Volume1035
DOIs
StatePublished - 2004

Fingerprint

Myelitis
Spinal Cord Injuries
Complement System Proteins
Viruses
Spinal Cord
Wounds and Injuries
Proteins
Contusions
Complement Activation
Recovery of Function
Psychological Stress
Heparin
Anti-Inflammatory Agents
Coloring Agents
Therapeutics
Extremities
Animal Models
Macrophages
Infiltration
Pain

Keywords

  • Inflammation
  • Spinal cord injury
  • Vaccinia virus complement control protein

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. / Reynolds, David N.; Smith, Scott A.; Zhang, Yi P.; Mengsheng, Qiu; Lahiri, Debomoy; Morassutti, Dante J.; Shields, Christopher B.; Kotwal, Girish J.

In: Annals of the New York Academy of Sciences, Vol. 1035, 2004, p. 165-178.

Research output: Contribution to journalArticle

Reynolds, David N. ; Smith, Scott A. ; Zhang, Yi P. ; Mengsheng, Qiu ; Lahiri, Debomoy ; Morassutti, Dante J. ; Shields, Christopher B. ; Kotwal, Girish J. / Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1035. pp. 165-178.
@article{6b0dbf872d5048efadb0946c4708eb8f,
title = "Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury",
abstract = "Traumatic spinal cord injury (SCI) claims approximately 10,000 new victims each year in the United States alone. The injury usually strikes those under the age of 30 years, often leading to a lifetime of pain, suffering, and disability. Therapeutic agents targeting spinal cord injury are sorely lacking, and therefore our laboratory endeavored to evaluate the potential therapeutic benefits of immediate post-injury administration of the vaccinia virus complement control protein (VCP). VCP is a multifunctional anti-inflammatory protein that can inhibit both pathways of complement activation and bind heparin. Utilizing a common animal model of contusion SCI, motor function recovery tests, and immunochemical stains, we evaluated the effects of VCP injected into spinal cord tissue following injury. Results demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves hind-limb function, establishing VCP as a strong candidate for further investigation in the treatment of SCI.",
keywords = "Inflammation, Spinal cord injury, Vaccinia virus complement control protein",
author = "Reynolds, {David N.} and Smith, {Scott A.} and Zhang, {Yi P.} and Qiu Mengsheng and Debomoy Lahiri and Morassutti, {Dante J.} and Shields, {Christopher B.} and Kotwal, {Girish J.}",
year = "2004",
doi = "10.1196/annals.1332.011",
language = "English",
volume = "1035",
pages = "165--178",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury

AU - Reynolds, David N.

AU - Smith, Scott A.

AU - Zhang, Yi P.

AU - Mengsheng, Qiu

AU - Lahiri, Debomoy

AU - Morassutti, Dante J.

AU - Shields, Christopher B.

AU - Kotwal, Girish J.

PY - 2004

Y1 - 2004

N2 - Traumatic spinal cord injury (SCI) claims approximately 10,000 new victims each year in the United States alone. The injury usually strikes those under the age of 30 years, often leading to a lifetime of pain, suffering, and disability. Therapeutic agents targeting spinal cord injury are sorely lacking, and therefore our laboratory endeavored to evaluate the potential therapeutic benefits of immediate post-injury administration of the vaccinia virus complement control protein (VCP). VCP is a multifunctional anti-inflammatory protein that can inhibit both pathways of complement activation and bind heparin. Utilizing a common animal model of contusion SCI, motor function recovery tests, and immunochemical stains, we evaluated the effects of VCP injected into spinal cord tissue following injury. Results demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves hind-limb function, establishing VCP as a strong candidate for further investigation in the treatment of SCI.

AB - Traumatic spinal cord injury (SCI) claims approximately 10,000 new victims each year in the United States alone. The injury usually strikes those under the age of 30 years, often leading to a lifetime of pain, suffering, and disability. Therapeutic agents targeting spinal cord injury are sorely lacking, and therefore our laboratory endeavored to evaluate the potential therapeutic benefits of immediate post-injury administration of the vaccinia virus complement control protein (VCP). VCP is a multifunctional anti-inflammatory protein that can inhibit both pathways of complement activation and bind heparin. Utilizing a common animal model of contusion SCI, motor function recovery tests, and immunochemical stains, we evaluated the effects of VCP injected into spinal cord tissue following injury. Results demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves hind-limb function, establishing VCP as a strong candidate for further investigation in the treatment of SCI.

KW - Inflammation

KW - Spinal cord injury

KW - Vaccinia virus complement control protein

UR - http://www.scopus.com/inward/record.url?scp=14944344788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944344788&partnerID=8YFLogxK

U2 - 10.1196/annals.1332.011

DO - 10.1196/annals.1332.011

M3 - Article

C2 - 15681807

AN - SCOPUS:14944344788

VL - 1035

SP - 165

EP - 178

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -